Jazz Pharmaceuticals and BeiGene’s Promising Phase 3 Study for Advanced Gastric and Esophageal Cancers

Jazz Pharmaceuticals ((JAZZ)), Beigene, Ltd. ((ONC)) announced an update on their ongoing clinical study.

Jazz Pharmaceuticals and BeiGene, Ltd. are conducting a Phase 3 study titled A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA). The study aims to assess the safety and efficacy of zanidatamab, with or without tislelizumab, compared to trastuzumab in patients with advanced HER2-positive gastric and esophageal cancers. This research is significant as it explores potentially more effective treatment options for these challenging cancer types.

The study tests zanidatamab, an investigational drug, in combination with chemotherapy, with or without the addition of tislelizumab, an immune checkpoint inhibitor. These interventions are designed to target HER2-positive cancer cells and enhance the body’s immune response against tumors.

This interventional study is randomized and follows a parallel assignment model without masking, meaning all participants and researchers know which treatments are being administered. The primary purpose is to evaluate treatment efficacy and safety.

The study began on December 2, 2021, with an estimated primary completion date in June 2025. The last update was submitted on June 26, 2025. These dates are crucial for tracking the study’s progress and anticipating results.

The outcome of this study could significantly affect Jazz Pharmaceuticals’ and BeiGene’s stock performance, as successful results may enhance their market position in oncology. Investors should watch for updates, as positive findings could shift market dynamics, especially in the competitive landscape of cancer therapeutics.

The study is ongoing, with further details available on the ClinicalTrials portal.